Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI method may spare kidney patients unnecessary biopsies

NCT ID NCT06126159

Diagnosis Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special MRI can tell the difference between harmless and cancerous kidney growths when standard CT scans cannot see fat. About 44 adults with kidney masses that have no visible fat on CT will get this advanced MRI. The goal is to see if the MRI can identify tumor types and guide treatment without needing a needle biopsy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
multiparametric and fat-detection magnetic resonance imaging (MRI)
What this could lead to
If successful, this MRI method could help doctors diagnose kidney tumor types without needing a biopsy, guiding treatment decisions more safely.
What could go wrong
This is a small, early-stage study with only 44 participants, so results may not apply to everyone. The MRI technique may not be accurate enough to replace biopsy in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 20 years old 2. Have renal parenchymal masses with no detectable intra-tumoral fat on computed tomography (CT) 3. Normal renal function (i.e.: estimated glomerular filtration rate ≧ 60 mL/min/1.73 m2) 4. No allergy history of iodinated contrast medium Exclusion Criteria: 1. Pregnant or lactating woman 2. Withdrawal of informed consent 3. Those who have not completed MRI 4. Those who did not receive renal tumor biopsy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

angiomyolipoma kidney cancer kidney neoplasm renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney neoplasms

Contacts and locations

Locations

  • Li-Jen Wang

    Taoyuan, Taiwan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.